{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.6","upperLimit":"26.5","value":"15.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"description":"Overall response is defined as participants with a best overall response of complete response (CR), partial response (PR) or stable disease (SD) after 4 cycles, assessed by the Investigator using tumor measurement and according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n\nCR: Disappearance of all target and non-target lesions and no new lesions;\n\nPR: Disappearance of all target lesions, persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits and no lesions, or, at least a 30% decrease in the size of target lesions and no progression of existing non-target lesions or any new lesions.\n\nSD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest size since the treatment started, and no progression of existing non-target lesions or any new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment.","id":"OG000","title":"P2 ST: CFZ 20/36 mg/m² Bolus"}],"paramType":"NUMBER","populationDescription":"Phase 2 Safety population","reportingStatus":"POSTED","timeFrame":"4 months","title":"Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles","type":"PRIMARY","unitOfMeasure":"percentage of participants"}